Genor BioPharma Co., Ltd. - Product Pipeline Review - 2014

  • ID: 2826079
  • Company Profile
  • 38 pages
  • Global Markets Direct
1 of 4
Genor BioPharma Co., Ltd. - Product Pipeline Review - 2014

Summary

Global Markets Direct’s, ‘Genor BioPharma Co., Ltd. - Product Pipeline Review - 2014’, provides an overview of the Genor BioPharma Co., Ltd.’s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Genor BioPharma Co., Ltd.’s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides brief overview of Genor BioPharma Co., Ltd. including business description, key information and facts, and its locations and subsidiaries
- The report reviews current pipeline of Genor BioPharma Co., Ltd.’s human therapeutic division and enlists all their major and minor projects
- The report features product description and descriptive mechanism of action for key pipeline products along with the product’s developmental history and major milestones
- Special feature on out-licensed and partnered product portfolio
- The report summarizes all the dormant and discontinued pipeline projects
- Latest company statement
- Latest news and deals relating to the Genor BioPharma Co., Ltd.’s pipeline products

Reasons to buy

- Evaluate Genor BioPharma Co., Ltd.’s strategic position with total access to detailed information on its product pipeline
- Assess the growth potential of Genor BioPharma Co., Ltd. in its therapy areas of focus
- Identify new drug targets and therapeutic classes in the Genor BioPharma Co., Ltd.’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
- Develop strategic initiatives by understanding the focus areas of Genor BioPharma Co., Ltd. and exploit collaboration and partnership opportunities
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Plan mergers and acquisitions effectively by identifying the most promising pipeline of Genor BioPharma Co., Ltd.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Explore the dormant and discontinued projects of Genor BioPharma Co., Ltd. and identify potential opportunities in those areas
- Avoid Intellectual Property Rights related issues
READ MORE
Note: Product cover images may vary from those shown
2 of 4
Table of Contents
Table of Contents
List of Tables
List of Figures
Genor BioPharma Co., Ltd. Snapshot
Genor BioPharma Co., Ltd. Overview
Key Facts
Genor BioPharma Co., Ltd. - Research and Development Overview
Key Therapeutic Areas
Genor BioPharma Co., Ltd. - Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products - Monotherapy
Pipeline Products - Partnered Products
Partnered Products/Combination Treatment Modalities
Genor BioPharma Co., Ltd. - Pipeline Products Glance
Genor BioPharma Co., Ltd. - Clinical Stage Pipeline Products
Phase I Products/Combination Treatment Modalities
Genor BioPharma Co., Ltd. - Early Stage Pipeline Products
IND/CTA Filed Products/Combination Treatment Modalities
Preclinical Products/Combination Treatment Modalities
Discovery Products/Combination Treatment Modalities
Genor BioPharma Co., Ltd. - Unknown Stage Pipeline Products
Unknown Products/Combination Treatment Modalities
Genor BioPharma Co., Ltd. - Drug Profiles
trastuzumab biosimilar
Product Description
Mechanism of Action
R&D Progress
adalimumab biosimilar
Product Description
Mechanism of Action
R&D Progress
infliximab biosimilar
Product Description
Mechanism of Action
R&D Progress
GB-222
Product Description
Mechanism of Action
R&D Progress
GB-241
Product Description
Mechanism of Action
R&D Progress
GB-243
Product Description
Mechanism of Action
R&D Progress
GB-213
Product Description
Mechanism of Action
R&D Progress
GB-214
Product Description
Mechanism of Action
R&D Progress
GB-223
Product Description
Mechanism of Action
R&D Progress
GB-224
Product Description
Mechanism of Action
R&D Progress
GB-234
Product Description
Mechanism of Action
R&D Progress
GB-235
Product Description
Mechanism of Action
R&D Progress
RYI-008
Product Description
Mechanism of Action
R&D Progress
Genor BioPharma Co., Ltd. - Pipeline Analysis
Genor BioPharma Co., Ltd. - Pipeline Products by Target
Genor BioPharma Co., Ltd. - Pipeline Products by Route of Administration
Genor BioPharma Co., Ltd. - Pipeline Products by Molecule Type
Genor BioPharma Co., Ltd. - Pipeline Products by Mechanism of Action
Genor BioPharma Co., Ltd. - Recent Pipeline Updates
Genor BioPharma Co., Ltd. - Locations And Subsidiaries
Head Office
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Genor BioPharma Co., Ltd., Key Facts
Genor BioPharma Co., Ltd. - Pipeline by Indication, 2014
Genor BioPharma Co., Ltd. - Pipeline by Stage of Development, 2014
Genor BioPharma Co., Ltd. - Monotherapy Products in Pipeline, 2014
Genor BioPharma Co., Ltd. - Partnered Products in Pipeline, 2014
Genor BioPharma Co., Ltd. - Partnered Products/ Combination Treatment Modalities, 2014
Genor BioPharma Co., Ltd. - Phase I, 2014
Genor BioPharma Co., Ltd. - IND/CTA Filed, 2014
Genor BioPharma Co., Ltd. - Preclinical, 2014
Genor BioPharma Co., Ltd. - Discovery, 2014
Genor BioPharma Co., Ltd. - Unknown, 2014
Genor BioPharma Co., Ltd. - Pipeline by Target, 2014
Genor BioPharma Co., Ltd. - Pipeline by Route of Administration, 2014
Genor BioPharma Co., Ltd. - Pipeline by Molecule Type, 2014
Genor BioPharma Co., Ltd. - Pipeline Products by Mechanism of Action, 2014
Genor BioPharma Co., Ltd. - Recent Pipeline Updates, 2014

List of Figures
Genor BioPharma Co., Ltd. - Pipeline by Top 10 Indication, 2014
Genor BioPharma Co., Ltd. - Pipeline by Stage of Development, 2014
Genor BioPharma Co., Ltd. - Monotherapy Products in Pipeline, 2014
Genor BioPharma Co., Ltd. - Partnered Products in Pipeline, 2014
Genor BioPharma Co., Ltd. - Pipeline by Top 10 Target, 2014
Genor BioPharma Co., Ltd. - Pipeline by Top 10 Route of Administration, 2014
Genor BioPharma Co., Ltd. - Pipeline by Top 10 Molecule Type, 2014
Genor BioPharma Co., Ltd. - Pipeline Products by Top 10 Mechanism of Action, 2014 34
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
Note: Product cover images may vary from those shown
Adroll
adroll